Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing phase 4 study of Xiao'er Fengreqing Mixture in children with acute upper respiratory tract infection
ChiCTR1800014531Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xiao'er Fengreqing Mixture in upper respiratory infection (URI) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Time for main clinical symptoms to disappear. Started Feb 2018; status: recruiting.
02
Drugs
Xiao'er Fengreqing Mixture
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on ChiCTR1800014531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014531.